TLSI Insider: CFO Receives 200,000 RSUs and 290,000 Options
Rhea-AI Filing Summary
TriSalus Life Sciences insider award summary: Chief Financial Officer David Patience received equity awards on 08/14/2025 consisting of 200,000 restricted stock units (RSUs) payable in common stock and an employee stock option to purchase 290,000 shares at an exercise price of $3.88 per share. Following these grants, the reporting person beneficially owns 200,000 common shares and 290,000 option shares directly. The RSUs vest in four equal annual installments beginning July 1, 2026, subject to continued service. The option vests 25% on the one-year anniversary of the July 1, 2026 vesting commencement date, with the remainder vesting monthly thereafter until fully vested, and expires on 08/13/2035.
Positive
- Alignment with shareholders: Grants are equity-based (RSUs and options), tying CFO compensation to stock performance and retention.
- Clear vesting schedules: RSUs vest in four equal annual installments and the option includes a one-year cliff then monthly vesting, supporting long-term retention.
Negative
- Potential dilution: Awards add up to 490,000 shares that could become outstanding if RSUs vest and options are exercised.
- No performance conditions disclosed: Vesting is described as service-based only, with no performance metrics indicated in this filing.
Insights
TL;DR: Officer received meaningful equity compensation that aligns incentives but creates potential dilution.
The CFO's award combines 200,000 RSUs and a 290,000-share option at $3.88, establishing a long-term compensation profile tied to share performance and continued service. Vesting schedules stagger realization through 2026 start dates and extend up to 2035 for option exercise, which supports retention. These grants are routine for senior executives and signal management alignment with shareholders; however, they increase the pool of potentially dilutive securities that could convert into common shares if vested and exercised.
TL;DR: Standard executive equity grants with service-based vesting; consistent with retention practices.
The structure—RSUs payable in common stock and time-vested options—follows common governance practices to retain and incentivize senior officers. The RSU four-year annual vesting and the option's one-year cliff plus monthly vesting thereafter create multi-year retention triggers. Documentation provided includes clear vesting conditions tied to continued service; no performance conditions are disclosed in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 290,000 | $0.00 | -- |
| Grant/Award | Common Stock | 200,000 | $0.00 | -- |
Footnotes (1)
- Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on July 1, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of July 1, 2026 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.
